Membrane transporters in the SLC and ABC superfamilies are of enormous pharmacological importance, serving as critical determinants of drug disposition and response. Building on the extensive infrastructure established during the previous granting cycles, the proposed research will focus on transporters in the liver and kidney, which interact with virtually all known drugs in mediating drug disposition, response and toxicity. Through computationally driven functional studies and multiple clinical studies, the proposed research will test the hypothesis that genetic variants in membrane transporters contribute to variation in drug response. The functional genomic studies will have a major emphasis on variants in noncoding regions, expanding on our current efforts, which are focused largely on nonsynonymous variants. For these studies, we propose to: (a) functionally characterize variants within regulatory regions of transporter genes;(b) associate sequence variants with transporter expression levels in liver and kidney samples;and (c) develop predictive models for substrate-dependent effects of nonsynonymous variants. In addition to common variants, we will continue to study rare variants as our previous studies have demonstrated their functional importance. Three types of clinical studies will be performed: (a) genotype-driven hypothesis testing studies in SOPHIE, a unique cohort of healthy volunteers who have provided DNA and agreed to be called back for follow-up studies;(b) a large genomewide association study in African Americans of response to the anti-diabetic drug, metformin, a drug that interacts with multiple transporters;and (c) collaborative studies on clinical samples in which a custom-designed transporter-ADME SNP chip will be used to identify genetic variants in transporters that are determinants of toxicities and response to multiple drugs. Our project has recruited a world-class multidisciplinary research team with computational, experimental and clinical expertise, who will apply innovative methodologies including RNA-seq, Next-generation sequencing and multi-stage genomewide association analysis. Three research cores, bioinformatics, biostatistics and genomics, will provide support for these highly mechanistic and clinically important studies.

Public Health Relevance

Variation in drug response is a major health problem with many individuals failing to achieve therapeutic response or experiencing adverse reactions to clinically used drugs. This research will advance our knowledge of the mechanisms responsible for variation in drug response through the discovery of genetic variants in membrane transporters that determine drug levels in body tissues and in the blood.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19GM061390-15
Application #
8689077
Study Section
Special Emphasis Panel (ZRG1-GGG-M (52))
Program Officer
Long, Rochelle M
Project Start
2000-04-01
Project End
2015-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
15
Fiscal Year
2014
Total Cost
$3,400,326
Indirect Cost
$957,475
Name
University of California San Francisco
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Yee, S W; Giacomini, M M; Hsueh, C-H et al. (2016) Metabolomic and Genome-wide Association Studies Reveal Potential Endogenous Biomarkers for OATP1B1. Clin Pharmacol Ther 100:524-536
Zhou, Kaixin; Yee, Sook Wah; Seiser, Eric L et al. (2016) Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. Nat Genet 48:1055-9
Zheng, Yi; Chen, Xijing; Benet, Leslie Z (2016) Reliability of In Vitro and In Vivo Methods for Predicting the Effect of P-Glycoprotein on the Delivery of Antidepressants to the Brain. Clin Pharmacokinet 55:143-67
Benet, Leslie Z; Hosey, Chelsea M; Ursu, Oleg et al. (2016) BDDCS, the Rule of 5 and drugability. Adv Drug Deliv Rev 101:89-98
Rotroff, Daniel M; Oki, Noffisat O; Liang, Xiaomin et al. (2016) Pharmacometabolomic Assessment of Metformin in Non-diabetic, African Americans. Front Pharmacol 7:135
Yee, S W; Momozawa, Y; Kamatani, Y et al. (2016) Genomewide Association Studies in Pharmacogenomics: Meeting Report of the NIH Pharmacogenomics Research Network-RIKEN (PGRN-RIKEN) Collaboration. Clin Pharmacol Ther 100:423-426
Li, M; Seiser, E L; Baldwin, R M et al. (2016) ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia. Pharmacogenomics J :
Eclov, Rachel J; Kim, Mee J; Smith, Robin P et al. (2016) In Vivo Hepatic Enhancer Elements in the Human ABCG2 Locus. Drug Metab Dispos :
Hibma, Jennifer E; Zur, Arik A; Castro, Richard A et al. (2016) The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin. Clin Pharmacokinet 55:711-21
Yuan, Bo; Yoshino, Yuta; Fukushima, Hisayo et al. (2016) Multidrug resistance-associated protein 4 is a determinant of arsenite resistance. Oncol Rep 35:147-54

Showing the most recent 10 out of 129 publications